L.E.L. Hendriks

van der Wel, J. W. T., Ernst, S. M., Jebbink, M., van den Broek, D., Badrising, S. K., Steinbusch, L. C., Ruiter, G., Theelen, W. S. M. E., van Veggel, B. A. M. H., Smit, J., Dingemans, A. M., Paats, M. S., Dubbink, H. J., Hashemi, S. M. S., Radonic, T., Cohen, D., van der Wekken, A. J., ter Elst, A., Timens, W., ... de Langen, A. J. (2025). Determining the optimal approach to identify osimertinib resistance; the first line osimertinib cohort of the OSIRIS study. Lung Cancer, 209, Article 108783. https://doi.org/10.1016/j.lungcan.2025.108783

Huijs, J. W. J., Sadowska, A. M., Degens, J. H. R. J., Steendam, C. M. J., Bensch, F., Hijmering-Kappelle, L. B. M., de Schrevel, T. M. T., van Geffen, W. H., Youssef-El Soud, M., Steens, M. M. H., Pitz, C., De Ruysscher, D. K. M., & Hendriks, L. E. L. (2025). Clinical risk factors for developing brain metastases during first-line (chemo-)immunotherapy in patients with non-small cell lung cancer without known baseline brain metastases. Lung Cancer, 208, Article 108745. https://doi.org/10.1016/j.lungcan.2025.108745

Hendriks, L. E. L., Cortiula, F., Martins-Branco, D., Mariamidze, E., Popat, S., Reck, M., & ESMO Guidelines Committee (2025). Updated treatment recommendations for systemic treatment: from the ESMO non-oncogene addicted-metastatic NSCLC Living Guideline†. Annals of Oncology, 36(10), 1223-1227. https://doi.org/10.1016/j.annonc.2025.06.004

Ogliari, F. R., Menis, J., & Hendriks, L. E. L. (2025). Can the positive findings from POD1UM-304 improve patient care worldwide? The Lancet Respiratory medicine. Advance online publication. https://doi.org/10.1016/S2213-2600(25)00260-7

Halilaj, I., Lieverse, R., Oberije, C., Hendriks, L., Billiet, C., Joye, I., Van Eeckhout, B., Wind, A., Ankolekar, A., & Lambin, P. (2025). Improving Patient Engagement in Phase 2 Clinical Trials With a Trial-Specific Patient Decision Aid: Development and Usability Study. Journal of Medical Internet Research, 27, Article e71817. https://doi.org/10.2196/71817

Jongbloed, M., Bortolot, M., Willmann, J., Bartolomeo, V., Novoa, N. M., De Ruysscher, D. K. M., & Hendriks, L. E. L. (2025). Current Controversies and Challenges in Non-Oncogene-Addicted Synchronous Oligometastatic Non-Small Cell Lung Cancer: A Review. JAMA Oncology. Advance online publication. https://doi.org/10.1001/jamaoncol.2025.2891

Bortolot, M., Remon, J., Bironzo, P., Cortiula, F., Menis, J., Chan, S. W., van Geel, R., Reguart, N., Arrieta, O., Mountzios, G., Dingemans, A. M. C., Besse, B., & Hendriks, L. E. L. (2025). De-escalation strategies with targeted therapies in non-small cell lung cancer. Cancer Treatment Reviews, 139, Article 102995. https://doi.org/10.1016/j.ctrv.2025.102995

de Rouw, N., Otten, L.-S., Kicken, M. P., Piet, B., Biesma, B., van Veggel, B., Steendam, C. M. J., van den Borne, B., Hendriks, L. E. L., Croes, S., Dingemans, A.-M. C., Dumoulin, D. W., Mathijssen, R. H. J., Burgers, J. A., Huitema, A. D. R., Derijks, H. J., Deenen, M. J., van den Heuvel, M. M., & ter Heine, R. (2025). Folinic Acid Prophylaxis and Dose Adjustments Enable Safe Treatment with Pemetrexed in Patients with Renal Impairment. Clinical Pharmacology & Therapeutics, 118(3), 715-722. https://doi.org/10.1002/cpt.3735

Ogliari, F. R., Huijs, J. W. J., Jongbloed, M., Willmann, J., Hendriks, L. E. L., & De Ruysscher, D. K. M. (2025). Adjuvant radiotherapy in the era of new peri-operative systemic treatments for surgically resected non-small-cell lung cancer: where do we stand? Translational Lung Cancer Research, 14(8), 3142-3152. https://doi.org/10.21037/tlcr-2025-144

de Jong, W. K., van der Velde, F. T. A., Keijser, A., Groen, H. J. M., van Lindert, A. S. R., Vink, G. R., Hendriks, L. E. L., & van den Heuvel, M. M. (2025). DuTOC: The prospective Dutch Thoracic Oncology Cohort. Lung Cancer, 208, Article 108728. Advance online publication. https://doi.org/10.1016/j.lungcan.2025.108728